Immunopathogenesis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) Takashi Yamamura 1 , Hirohiko Ono 1 , Wakiro Sato 1 1Department of Immunology, National Institute of Neuroscience, National Center of Neurology and Psychiatry Keyword: 筋痛性脳脊髄炎/慢性疲労症候群 , 炎症性サイトカイン , 自己免疫 , ナチュラルキラー細胞 , リツキシマブ , myalgic encephalomyelitis/chronic fatigue syndrome , ME/CFS , proinflammatory cytokine , autoimmune , natural killer cell , rituximab pp.35-40
Published Date 2018/1/1
DOI https://doi.org/10.11477/mf.1416200947
  • Abstract
  • Look Inside
  • Reference


A recent study on the pathogenesis of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) has revealed an elevation of inflammatory and anti-inflammatory cytokines in the sera and cerebrospinal fluids of the patients and presence of autoantibodies in subgroups of ME/CFS patients. Furthermore, investigator-initiated clinical trials have proved the efficacy of anti-CD20 antibody (rituximab), that eliminate B cells, in the treatment of ME/CFS. Based on these findings, we hypothesize that immune abnormalities, such as enhanced autoimmune responses, may play an essential role in the neuroinflammatory pathogenesis of ME/CFS.

Copyright © 2018, Igaku-Shoin Ltd. All rights reserved.


電子版ISSN 1344-8129 印刷版ISSN 1881-6096 医学書院